Cargando…
The role of PD-1 and PD-L1 in T-cell immune suppression in patients with hematological malignancies
T-cell activation and dysfunction relies on direct and modulated receptors. Based on their functional outcome, co-signaling molecules can be divided as co-stimulators and co-inhibitors, which positively and negatively control the priming, growth, differentiation and functional maturation of a T-cell...
Autores principales: | Shi, Li, Chen, Shaohua, Yang, Lijian, Li, Yangqiu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3851976/ https://www.ncbi.nlm.nih.gov/pubmed/24283718 http://dx.doi.org/10.1186/1756-8722-6-74 |
Ejemplares similares
-
Do PD-1 and PD-L2 expressions have prognostic impact in hematologic malignancies?
por: KORKMAZ, Serdal, et al.
Publicado: (2019) -
Immune checkpoint blockade: the role of PD-1-PD-L axis in lymphoid malignancies
por: Ilcus, Cristina, et al.
Publicado: (2017) -
Immune Suppression by Neutrophils in HIV-1 Infection: Role of PD-L1/PD-1 Pathway
por: Bowers, Nathan L., et al.
Publicado: (2014) -
Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies
por: Wang, Dongxu, et al.
Publicado: (2019) -
The role of PD-1/PD-L1 and application of immune-checkpoint inhibitors in human cancers
por: Tang, Qing, et al.
Publicado: (2022)